Targeted therapy of non-small-cell lung carcinoma

Therapeutic Advances in Respiratory Disease

Volumn 6, Issue 1, 2012, Pages 41-56

  Tiwari, Divya ^a   Brodie, Seth A ^a   Brandes, Johann C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR; lung cancer; targeted therapy; VEGF

Indexed keywords

ADENOSINE TRIPHOSPHATE; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; GEFITINIB; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMATINIB; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN RECEPTOR; SORAFENIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VORINOSTAT;

ADJUVANT THERAPY; ANGIOGENESIS; APOPTOSIS; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; DISEASE COURSE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVATION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVATION; GENE CONTROL; GENE INACTIVATION; GENE MUTATION; HEMOPTYSIS; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; METHYLATION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DESIGN; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 84856595031     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465811404590     Document Type: Review

References (86)

1. Belinsky S.A. Nikula K.J. Palmisano W.A. Michels R. Saccomanno G. Gabrielson E. (1998) Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 95: 11891–11896.
2. Belinsky S.A. Palmisano W.A. Gilliland F.D. Crooks L.A. Divine K.K. Winters S.A. (2002) Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370–2377.
3. Bell D.W. Lynch T.J. Haserlat S.M. Harris P.L. Okimoto R.A. Brannigan B.W. (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23: 8081–8092.
4. Bezjak A. Tu D. Seymour L. Clark G. Trajkovic A. Zukin M. (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24: 3831–3837.
5. Brose M.S. Volpe P. Feldman M. Kumar M. Rishi I. Gerrero R. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997–7000.
6. Cappuzzo F. Ciuleanu T. Stelmakh L. Cicenas S. Szczesna A. Juhasz E. (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521–529.
7. Chang A. Parikh P. Thongprasert S. Tan E.H. Perng R.P. Ganzon D. (2006) Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 1: 847–855.
8. Chang G.C. Hsu S.L. Tsai J.R. Liang F.P. Lin S.Y. Sheu G.T. (2004) Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol 68: 1453–1464.
9. Chen Z. Sasaki T. Tan X. Carretero J. Shimamura T. Li D. (2010) Inhibition of ALK, PI3K/MEK and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene. Cancer Res 70: 9827–9836.
10. Ciuleanu T. Brodowicz T. Zielinski C. Kim J.H. Krzakowski M. Laack E. (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432–1440.
11. Crino L. Dansin E. Garrido P. Griesinger F. Laskin J. Pavlakis N. (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11: 733–740.
12. Damiani L.A. Yingling C.M. Leng S. Romo P.E. Nakamura J. Belinsky S.A. (2008) Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res 68: 9005–9014.
13. De Boer R. Arrieta Ó. Gottfried M. Blackhall F.H. Raats J. Yang C.H. (2009) Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J Clin Oncol 27(15 Suppl.): 8010.
14. Douillard J.Y. Shepherd F.A. Hirsh V. Mok T. Socinski M.A. Gervais R. (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28: 744–752.
15. Engelman J.A. Zejnullahu K. Mitsudomi T. Song Y. Hyland C. Park J.O. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043.
16. Fisher G.H. Wellen S.L. Klimstra D. Lenczowski J.M. Tichelaar J.W. Lizak M.J. (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249–3262.
17. Folkman J. Merler E. Abernathy C. Williams G. (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275–288.
18. Fong P.C. Boss D.S. Yap T.A. Tutt A. Wu P. Mergui-Roelvink M. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123–134.
19. Fukuoka M. Yano S. Giaccone G. Tamura T. Nakagawa K. Douillard J.Y. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237–2246.
20. Gandara D. Kim E.S. Herbst R.S. Moon J. Redman M.W. Dakhil S.R. (2010) S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol 27(15 Suppl.): 8015.
21. Gatzemeier U. Pluzanska A. Szczesna A. Kaukel E. Roubec J. De Rosa F. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25: 1545–1552.
22. Giaccone G. Herbst R.S. Manegold C. Scagliotti G. Rosell R. Miller V. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 22: 777–784.
23. Goss G.D. Lorimer I. Tsao M.S. O–Callaghan C.J. Ding K. Masters G.A. (2010) A phase III randomized, double-blind, placebo controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB–IIIA NSCLC. In: Proceedings of the ASCO 2010, Chicago. J Clin Oncol 28(Suppl.): 18s.
24. Herbst R.S. Giaccone G. Schiller J.H. Natale R.B. Miller V. Manegold C. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 22: 785–794.
25. Herbst R.S. O–Neill V.J. Fehrenbacher L. Belani C.P. Bonomi P.D. Hart L. (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25: 4743–4750.
26. Herbst R.S. Prager D. Hermann R. Fehrenbacher L. Johnson B.E. Sandler A. (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892–5899.
27. Herbst R.S. Sun Y. Eberhardt W.E. Germonpre P. Saijo N. Zhou C. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11: 619–626.
28. Herman J.G. Baylin S.B. (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042–2054.
29. Hirsch F.R. Varella-Garcia M. Bunn P.A. Jr Franklin W.A. Dziadziuszko R. Thatcher N. (2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24: 5034–5042.
30. Janne P.A. von Pawel J. Cohen R.B. Crino L. Butts C.A. Olson S.S. (2007) Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 25: 3936–3944.
31. Janne P.A. Wang X.F. Socinski M.A. Crawford J. Capelletti M. Edelman M.J. (2010) Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol 28(15 Suppl.): 7503.
32. Jassem J. Langer C.J. Karp D.D. Mok T. Benner R.J. Green S.J. (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28(15 Suppl.): 7500.
33. Jemal A. Siegel R. Xu J. Ward E. (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
34. Ji H. Li D. Chen L. Shimamura T. Kobayashi S. McNamara K. (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9: 485–495.
35. Johnson D.H. Fehrenbacher L. Novotny W.F. Herbst R.S. Nemunaitis J.J. Jablons D.M. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184–2191.
36. Karp D.D. Paz-Ares L.G. Novello S. Haluska P. Garland L. Cardenal F. (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27: 2516–2522.
37. Keck P.J. Hauser S.D. Krivi G. Sanzo K. Warren T. Feder J. (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309–1312.
38. Kelly K. Chansky K. Gaspar L.E. Albain K.S. Jett J. Ung Y.C. (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26: 2450–2456.
39. Khambata-Ford S. Harbison C.T. Hart L.L. Awad M. Xu L.A. Horak C.E. (2010) Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 28: 918–927.
40. Kim E.S. Hirsh V. Mok T. Socinski M.A. Gervais R. Wu Y.L. (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809–1818.
41. Koivunen J.P. Mermel C. Zejnullahu K. Murphy C. Lifshits E. Holmes A.J. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275–4283.
42. Kris M.G. Natale R.B. Herbst R.S. Lynch T.J. Jr Prager D. Belani C.P. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149–2158.
43. Kwak E.L. Bang Y.J. Camidge D.R. Shaw A.T. Solomon B. Maki R.G. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693–1703.
44. Lee L. Hirsh V. Park K. Qinn S. Plajman C.R. Perng R. (2010) Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 28(25 Suppl.): 7525.
45. Leidner R.S. Fu P. Clifford B. Hamdan A. Jin C. Eisenberg R. (2009) Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 27: 5620–5626.
46. Leung D.W. Cachianes G. Kuang W.J. Goeddel D.V. Ferrara N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309.
47. Licchesi J.D. Westra W.H. Hooker C.M. Herman J.G. (2008a) Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 14: 2570–2578.
48. Licchesi J.D. Westra W.H. Hooker C.M. Machida E.O. Baylin S.B. Herman J.G. (2008b) Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 29: 895–904.
49. Lynch T.J. Bell D.W. Sordella R. Gurubhagavatula S. Okimoto R.A. Brannigan B.W. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.
50. Lynch T.J. Patel T. Dreisbach L. McCleod M. Heim W.J. Hermann R.C. (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28: 911–917.
51. Maemondo M. Inoue A. Kobayashi K. Sugawara S. Oizumi S. Isobe H. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380–2388.
52. McCabe M.T. Brandes J.C. Vertino P.M. (2009) Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 15: 3927–3937.
53. Mitsudomi T. Morita S. Yatabe Y. Negoro S. Okamoto I. Tsurutani J. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121–128.
54. Mok T.S. Wu Y.L. Thongprasert S. Yang C.H. Chu D.T. Saijo N. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957.
55. Morgillo F. Kim W.Y. Kim E.S. Ciardiello F. Hong W.K. Lee H.Y. (2007) Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13: 2795–2803.
56. Morgillo F. Woo J.K. Kim E.S. Hong W.K. Lee H.Y. (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66: 10100–10111.
57. Natale R.B. Thongprasert S. Greco F.A. Thomas M. Tsai C.M. Sunpaweravong P. (2009) Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). J Clin Oncol 27(15 Suppl.): 8009.
58. Owonikoko T.K. Ramalingam S.S. Behera M. Brande S.J.C. Saba N. Bhimani C. (2010) Survival impact of newly approved therapeutic agents in patients with advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database analysis. J Clin Oncol 28(15 Suppl.): 7633.
59. Paez J.G. Janne P.A. Lee J.C. Tracy S. Greulich H. Gabriel S. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500.
60. Pao W. Miller V.A. Politi K.A. Riely G.J. Somwar R. Zakowski M.F. (2005a) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
61. Pao W. Wang T.Y. Riely G.J. Miller V.A. Pan Q. Ladanyi M. (2005b) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS medicine 2: e17.
62. Pirker R. Pereira J.R. Szczesna A. von Pawel J. Krzakowski M. Ramlau R. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525–1531.
63. Ramalingam S.S. Harvey R.D. Saba N. Owonikoko T.K. Kauh J. Shin D.M. (2010a) Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 116: 3903–3909.
64. Ramalingam S.S. Maitland M.L. Frankel P. Argiris A.E. Koczywas M. Gitlitz B. (2010b) Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28: 56–62.
65. Reck M. von Pawel J. Zatloukal P. Ramlau R. Gorbounova V. Hirsh V. (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804–1809.
66. Reck M. von Pawel J. Zatloukal P. Ramlau R. Gorbounova V. Hirsh V. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227–1234.
67. Riely G.J. Kris M.G. Rosenbaum D. Marks J. Li A. Chitale D.A. (2008) Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731–5734.
68. Riely G.J. Rizvi N.A. Kris M.G. Milton D.T. Solit D.B. Rosen N. (2009) Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 27: 264–270.
69. Sandler A. Gray R. Perry M.C. Brahmer J. Schiller J.H. Dowlati A. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550.
70. Scagliotti G. Novello S. von Pawel J. Reck M. Pereira J.R. Thomas M. (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28: 1835–1842.
71. Sequist L.V. Besse B. Lynch T.J. Miller V.A. Wong K.K. Gitlitz B. (2010) Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 3076–3083.
72. Shaw A.T. Yeap B.Y. Mino-Kenudson M. Digumarthy S.R. Costa D.B. Heist R.S. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247–4253.
73. Shepherd F.A. Rodrigues Pereira J. Ciuleanu T. Tan E.H. Hirsh V. Thongprasert S. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132.
74. Socinski M.A. Langer C.J. Huang J.E. Kolb M.M. Compton P. Wang L. (2009) Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27: 5255–5261.
75. Soda M. Choi Y.L. Enomoto M. Takada S. Yamashita Y. Ishikawa S. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561–566.
76. Thatcher N. Chang A. Parikh P. Rodrigues Pereira J. Ciuleanu T. von Pawel J. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527–1537.
77. Tol J. Koopman M. Cats A. Rodenburg C.J. Creemers G.J. Schrama J.G. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563–572.
78. Tucker C.L. Fields S. (2003) Lethal combinations. Nat Genet 35: 204–205.
79. Ueda M. Toji E. Nunobiki O. Izuma S. Okamoto Y. Torii K. (2008) Mutational analysis of the BRAF gene in human tumor cells. Hum Cell 21: 13–17.
80. Van Cutsem E. Kohne C.H. Hitre E. Zaluski J. Chang Chien C.R. Makhson A. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408–1417.
81. Weinstein I.B. Begemann M. Zhou P. Han E.K. Sgambato A. Doki Y. (1997) Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 3: 2696–2702.
82. Wheatley-Price P. Ding K. Seymour L. Clark G.M. Shepherd F.A. (2008) Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 2350–2357.
83. Yamamoto H. Shigematsu H. Nomura M. Lockwood W.W. Sato M. Okumura N. (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68: 6913–6921.
84. Yun C.H. Mengwasser K.E. Toms A.V. Woo M.S. Greulich H. Wong K.K. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070–2075.
85. Zhou C. Wu Y.-L. Chen G. Feng J. Liu X. Wang C. (2010) Efficacy results from the randomised phase III optimal (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced nonsmall-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Ann Oncol 21(Suppl. 8): LBA 13.
86. Zhou W. Ercan D. Chen L. Yun C.H. Li D. Capelletti M. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070–1074.